Shire, the specialty pharma company, may need to find an antidote for a poison pill before it can win shareholders in Baxalta over to its $30bn bid.» Read More
The federal government says health care facilities should stop using Hospira's Symbiq medication infusion pump because its vulnerable to hacking.
The U.S. and 11 Pacific nations failed to reach a trade agreement, with talks on the largest regional trade agreement ever ending in deadlock.
A vaccine being developed by Merck and NewLink was shown to be 100 percent effective, but does this mean they'll make big bucks?
CVS spokesman Michael DeAngelis said the Rhode Island-based company had not been served with the lawsuit, so he couldn't comment.
Former Allergan CEO David Pyott tells a Senate hearing the SEC should investigate the Pershing Square-Valeant alliance.
GlaxoSmithKline shares jumped 3 percent after the U.K.-listed pharmaceutical giant reported second-quarter earnings per share that were slightly higher than forecast on Wednesday.
The CEO of German drugmaker Bayer has quashed any talk of acquiring its competitor Syngenta, which is being pursued by U.S. firm Monsanto.
Gilead blew past top and bottom line expectations on the strength of strong sales for its hepatitis C treatments.
Barbara Ryan, Clermont Partners, breaks down Pfizer and Merck's quarterly results and shares her outlook on the pharmaceutical sector.
Teva will acquire Allergan's generics unit for $40.5 billion. CNBC's Meg Tirrell takes a look at other potential M&A action in the space.
Chart analyst John Kosar shows how investors can profit from the pullback in oil prices.
Allergan chief Brent Saunders says the sale of its generics business would allow the company to double down on its higher margin branded business.
One large pharmacy benefit manager warns that costs from new PCSK9 drugs could reach as high as $150 billion annually.
CNBC's Meg Tirrell reports on the FDA approving Regeneron's cholesterol drug Praluent.
Shares of Regeneron were down about 3 percent after the FDA approved Regeneron's cholesterol-lowering drug Praluent on Friday.
CNBC's Meg Tirrell reports on a Glaxo Malaria vaccine for use in Sub-Saharan Africa as it seeks the final steps to approval.
CNBC's Meg Tirrell looks ahead at pharma earnings to come. FMHR traders weigh in on the health care space.
CNBC's Meg Tirrell reports on Biogen's sales growth as the company misses sales estimates.
Biogen shares sank after it lowered its 2015 forecast on slower-than-anticipated growth of its multiple sclerosis blockbuster Tecfidera.
Jim Cramer explains why he is watching shares of Biogen after the company lowered its guidance
Get the best of CNBC in your inbox